Literature DB >> 12493786

In vitro susceptibilities of zygomycetes to conventional and new antifungals.

Eric Dannaoui1, Joseph Meletiadis, Johan W Mouton, Jacques F G M Meis, Paul E Verweij.   

Abstract

In vitro susceptibilities of 36 zygomycete isolates, belonging to six genera, to itraconazole, posaconazole, voriconazole, terbinafine, amphotericin B and 5-fluorocytosine were determined by using a broth microdilution adaptation of the National Committee for Clinical Laboratory Standards M-38P reference method. The influence of incubation time on MIC values, and the performance of a spectrophotometric method for MIC determination in comparison with the visual reference method, were also evaluated. Amphotericin B was active against most of the isolates. All the isolates were highly resistant to 5-fluorocytosine (MICs > 256 mg/L). Voriconazole was significantly less active than the other drugs with an overall MIC(90) (MIC at which 90% of the isolates were inhibited) of 32 mg/L. In contrast, posaconazole showed good activity (MIC(90) 1 mg/L). A wide range of MICs, from 0.03 to > or =32 mg/L, was obtained for itraconazole and terbinafine. Differences in susceptibility between and within genera were noted. Rhizopus spp. were significantly less susceptible to itraconazole, posaconazole, terbinafine and amphotericin B than Absidia spp., and less susceptible than Mucor spp. to amphotericin B. Terbinafine appeared to be more active against Rhizopus microsporus than against Rhizopus oryzae (geometric mean MIC of 0.15 and 64 mg/L, respectively). The activity of the drugs was dependent on the incubation period. A significant increase in MICs was noted between 24 and 48 h of incubation. On the other hand, the two methods used for MIC determination (visual and spectrophotometric readings) showed good agreement. These results suggest that the zygomycetes are a heterogeneous group for antifungal susceptibility. Some of the conventional and new antifungals are effective in vitro; their efficacies in vivo remain to be determined. The spectrophotometric method appears to be a valuable alternative to the visual method for MIC determination for zygomycetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493786     DOI: 10.1093/jac/dkg020

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  77 in total

1.  In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.

Authors:  Sharon C-A Chen; Chayanika Biswas; Robyn Bartley; Fred Widmer; Namfon Pantarat; Daniel Obando; Julianne T Djordjevic; David H Ellis; Katrina A Jolliffe; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

2.  Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.

Authors:  Roxana G Vitale; G Sybren de Hoog; Patrick Schwarz; Eric Dannaoui; Shuwen Deng; Marie Machouart; Kerstin Voigt; Wendy W J van de Sande; Somayeh Dolatabadi; Jacques F Meis; Grit Walther
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

Review 3.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

4.  Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry.

Authors:  Wieland Schrödl; Tilo Heydel; Volker U Schwartze; Kerstin Hoffmann; Anke Grosse-Herrenthey; Grit Walther; Ana Alastruey-Izquierdo; Juan Luis Rodriguez-Tudela; Philipp Olias; Ilse D Jacobsen; G Sybren de Hoog; Kerstin Voigt
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

5.  Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.

Authors:  Ana Alastruey-Izquierdo; Isabel Cuesta; Grit Walther; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

6.  Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

7.  Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.

Authors:  Angela Sansone-Parsons; Gopal Krishna; Angela Calzetta; David Wexler; Bhavna Kantesaria; Mitchell A Rosenberg; Marc A Saltzman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

8.  Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

Authors:  Ana Alastruey-Izquierdo; Maria Victoria Castelli; Isabel Cuesta; Araceli Monzon; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

9.  Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.

Authors:  Zia U Khan; Suhail Ahmad; Arnost Brazda; Rachel Chandy
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

10.  Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

Authors:  Susanne Perkhofer; Maria Locher; Manuel Cuenca-Estrella; Reinhard Rüchel; Reinhard Würzner; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.